Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
As of today, Eli Lilly(LLY) shares are valued at $1,081.69. The company's market cap stands at 1.02T, with a P/E ratio of 51.50 and a dividend yield of 57.6%.
On 2026-01-21, Eli Lilly(LLY) stock moved within a range of $1,038.01 to $1,082.00. With shares now at $1,081.69, the stock is trading +4.2% above its intraday low and -0.0% below the session's peak.
Trading volume for Eli Lilly(LLY) stock has reached 3.69M, versus its average volume of 3M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.
LLY News
Earlier this month, Eli Lilly and Company received U.S. FDA Breakthrough Therapy designation for sofetabart mipitecan, a folate receptor alpha-targeting antibod...
Stocks Jump As Trump Halts Greenland Tariffs; Eli Lilly, Google, Zions In Focus 8:30 AM ET Ken Shreve and Ed Carson analyze Wednesday's market action and discu...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Eli Lilly Advances New Oral Drug for Diabetic...
Analyst ratings
80%
of 30 ratingsMore LLY News
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Eli Lilly’s Knee Osteoarthritis Obesity Trial...
Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for sofetabart mipitecan, an ovarian cancer drug candidate. The designation covers treatment...
Drugmakers, which have spent the past six months reaching tariff deals with Trump, seem to expect some immunity from a new batch of tariffs on European countrie...
Abivax (ABVX) CEO Marc de Garidel has dismissed rumors that U.S. pharmaceutical giant Eli Lilly (LLY) is planning to make a takeover bid for the French company...
Commenting on reports that Eli Lilly (LLY) has approached the French government to acquire Abivax (ABVX), Marc de Garidel, CEO of the Paris-based biotech, denie...
Eli Lilly (LLY) announced that the FDA has granted Breakthrough Therapy designation to sofetabart mipitecan for the treatment of adult patients with platinum-re...
Key Points Abivax has a potential transformative medicine in its pipeline that is attracting attention from other drugmakers. If the biotech gets acquired thi...
